Sat.Mar 25, 2023 - Fri.Mar 31, 2023

article thumbnail

Woman of the Week: Psilera’s Jackie von Salm

PharmaVoice

Psilera founder’s “third eye” approach to psychedelics ushers them into the therapeutic realm

105
105
article thumbnail

Signify Health CEO says CVS deal will 'turbocharge' home health provider's roadmap

Fierce Healthcare

Signify Health CEO says CVS deal will 'turbocharge' home health provider's roadmap hlandi Wed, 03/29/2023 - 19:57

110
110
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

BioNTech surprises analysts with low revenue guidance as COVID-19 vaccine demand wavers

Fierce Pharma

BioNTech surprises analysts with low revenue guidance as COVID-19 vaccine demand wavers fkansteiner Mon, 03/27/2023 - 09:35

Vaccines 111
article thumbnail

BioNTech targets infectious diseases for vaccine development

Pharmaceutical Technology

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. In its FY 2022 report, BioNTech has identified herpes simplex virus (HSV), malaria, and shingles as disease targets.

Vaccines 106
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.

article thumbnail

SCOTUS to decide ‘fundamental change’ in biologics patents with fate of Amgen v. Sanofi

PharmaVoice

The Supreme Court will now decide whether Amgen can protect Repatha as a whole class of drugs or whether Sanofi’s rival product Praluent can retain a place in the market

98
article thumbnail

UnitedHealthcare to begin reducing prior authorizations this summer

Fierce Healthcare

UnitedHealthcare to begin reducing prior authorizations this summer pminemyer Wed, 03/29/2023 - 17:02

110
110

More Trending

article thumbnail

Viking’s weight loss drug enters an already crowded arena

Pharmaceutical Technology

Viking Therapeutics has announced the start of a Phase I clinical study to evaluate its dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist VK2735.

Dosage 98
article thumbnail

Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries

Fierce Pharma

Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries esagonowsky Mon, 03/27/2023 - 09:19

102
102
article thumbnail

ViVE 2023: Amazon Pharmacy integrates coupons in latest bid to target affordability of branded drugs

Fierce Healthcare

ViVE 2023: Amazon Pharmacy integrates coupons in latest bid to target affordability of branded drugs hlandi Tue, 03/28/2023 - 15:24

107
107
article thumbnail

FDA releases draft of accelerated approval guidance for oncology therapeutics

Pharmafile

The FDA has released a draft of new guidance for accelerated approval for oncology therapeutics, highlighting the need for stricter clinical trial design. read more Medical Communications

FDA 72
article thumbnail

Regeneron and Sonoma Biotherapeutics partner to develop T cell therapies

Pharmaceutical Technology

Regeneron Pharmaceuticals has collaborated with Sonoma Biotherapeutics to discover, develop and commercialise new regulatory T cell (Treg) therapies for autoimmune diseases.

98
article thumbnail

Duo no more: After M&A spree, Pfizer parts ways with Merck KGaA on Bavencio

Fierce Pharma

Duo no more: After M&A spree, Pfizer parts ways with Merck KGaA on Bavencio zbecker Mon, 03/27/2023 - 17:42

96
article thumbnail

ViVE 2023: UnitedHealth's new tech exec on how the payer giant is aiming to accelerate transformation

Fierce Healthcare

ViVE 2023: UnitedHealth's new tech exec on how the payer giant is aiming to accelerate transformation pminemyer Mon, 03/27/2023 - 22:48

110
110
article thumbnail

Netris Pharma doses first patient in pancreatic cancer study

Pharmafile

Netris Pharma has announced that it has dosed its first patient in the Lap-NET1 study for the safety and efficacy of anti-netrin-1 antibody NP137 in combination with mFOLFIRINOX as a first-line treatment for patients with locally advanced pancreatic ductal adenocarcinoma.

64
article thumbnail

Regenerative medicine: new focus on VEGF target?

Pharmaceutical Technology

Regenerative medicines in early-stage development (preclinical, discovery, or investigational new drug [IND]/ clinical trial application [CTA] filed status) have seen a change in drug targets compared to therapies in late-stage development (Phase II to pre-registration stage).

97
article thumbnail

Look out, Lilly. Novartis touts 'consistent benefit' for Kisqali in broad early-stage breast cancer

Fierce Pharma

Look out, Lilly. Novartis touts 'consistent benefit' for Kisqali in broad early-stage breast cancer aliu Mon, 03/27/2023 - 10:51

96
article thumbnail

Hospitals feel congressional heat over compliance with price transparency rule

Fierce Healthcare

Hospitals feel congressional heat over compliance with price transparency rule rking Tue, 03/28/2023 - 17:11

Hospitals 105
article thumbnail

First immunotherapy recommended for advanced cervical cancer

European Pharmaceutical Review

Pembrolizumab (Keytruda) has been recommended in National Institute for Health and Care Excellence (NICE) final draft guidance for advanced cervical cancer.

article thumbnail

Vertex signs licence deal with CRISPR Therapeutics for diabetes therapies

Pharmaceutical Technology

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D).

article thumbnail

Another rare disease M&A deal? BridgeBio draws buyout interest from Big Pharma: Bloomberg

Fierce Pharma

Another rare disease M&A deal? BridgeBio draws buyout interest from Big Pharma: Bloomberg aliu Tue, 03/28/2023 - 10:22

90
article thumbnail

Value-based care enabler Wellvana clinches $84M to expand in existing, new markets

Fierce Healthcare

Value-based care enabler Wellvana clinches $84M to expand in existing, new markets agliadkovskaya Mon, 03/27/2023 - 14:48

107
107
article thumbnail

Genialis raises $13m in Series A funding for the development of AI/ML patient classifiers

Pharmafile

Genialis, a computational precision medicine company, has announced that it’s raised more than $13m in Series A funding, co-led by Taiwania Capital and Debiopharm Innovation Fund.

article thumbnail

UK boosts life science innovation with £277 million funding

Pharmaceutical Technology

On March 28, the UK government announced that four UK life sciences companies will receive £277 million to help fund and advance manufacturing projects in medical diagnostics and human medicines.

article thumbnail

With FDA nod for a Novartis castoff, Pharming is set to market a second rare disease drug

Fierce Pharma

With FDA nod for a Novartis castoff, Pharming is set to market a second rare disease drug kdunleavy Mon, 03/27/2023 - 10:40

FDA 91
article thumbnail

Bipartisan Senate bill aims to take on Medicare Advantage up-coding practices

Fierce Healthcare

Bipartisan Senate bill aims to take on Medicare Advantage up-coding practices rking Wed, 03/29/2023 - 17:02

99
article thumbnail

AbbVie’s upadacitinib meets primary endpoint in trial for systemic lupus erythematosus

Pharmafile

AbbVie has shared that upadacitinib (Rinvoq) has been shown to be effective in treating patients with moderately-to-severely-active systemic lupus erythematosus (SLE).

59
article thumbnail

Pharma’s salesforce is suffering — what does version 2.0 look like?

PharmaVoice

Ahead of turbulent market conditions, EY analyst Arda Ural encourages companies to rethink their sales strategy

59
article thumbnail

In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda

Fierce Pharma

In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda aliu Mon, 03/27/2023 - 15:40

90
article thumbnail

ViVe 2023: CancerX co-hosts Moffitt Cancer Center, Digital Medicine Society, unveil 'Moonshot' digital health effort

Fierce Healthcare

ViVe 2023: CancerX co-hosts Moffitt Cancer Center, Digital Medicine Society, unveil 'Moonshot' digital health effort hlandi Tue, 03/28/2023 - 07:36

98
article thumbnail

Novo Nordisk announces results from phase 3 PIONEER PLUS trial

Pharmafile

Novo Nordisk has announced headline results from the phase 3b PIONEER PLUS trial for the safety and efficacy of once-daily oral semaglutide 25mg and 50mg versus 14mg as an add-on to a stable dose of 1-3 oral antidiabetic medicines in patients with type 2 diabetes.

59
article thumbnail

What is a Digital Hub in 2023?

Pharmaceutical Commerce

Deciphering the different "technology-first” and “technology-enabled” patient support programs.

52
article thumbnail

FDA committee will hear Perrigo's OTC bid for birth control med Opill in May

Fierce Pharma

FDA committee will hear Perrigo's OTC bid for birth control med Opill in May kdunleavy Tue, 03/28/2023 - 14:47

FDA 82
article thumbnail

'Podnosis': Insight on the Ohio train derailment class-action lawsuit, and how data analytics can improve social risk factor identification

Fierce Healthcare

Podnosis': Insight on the Ohio train derailment class-action lawsuit, and how data analytics can improve social risk factor identification tcarey Tue, 03/28/2023 - 14:07

84
article thumbnail

Abberior installs new STED microscope at MBC BioLabs

Pharmafile

Abberior has announced that it has placed a super-resolution STED microscope at MBC BioLabs, which is the leading San Francisco Bay Area biotech incubator network.

article thumbnail

High-Tech Hubs and Specialty Pharma

Pharmaceutical Commerce

With the rapid rise of the specialty drug market, manufacturers are increasingly relying on new advances used by patient hubs to boost their levels of patient engagement.

52
article thumbnail

Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications

Fierce Pharma

Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications kdunleavy Wed, 03/29/2023 - 10:40

78